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Introduction
Following the discovery of hepatitis C virus (HCV) in 
1989 as the major etiological agent of non-A-non-B 
chronic hepatitis [1], some epidemiological studies 
suggested its possible role in the pathogenesis of mixed 
cryoglobulinemia syndrome (MCs), which now repre-
sents the prototype of HCV-associated autoimmune-
lymphoproliferative disorders [1-4]. Since the disease 
may mimic numerous immunological and neoplastic 
disorders, the discovery of its association with HCV 
infection prompted further clinical investigations into 
the possible pathogenetic role of HCV in other auto-
immune diseases [2,3]. In 2007, we proposed the term 
‘HCV syndrome’, which encompasses the wide spectrum 
of both hepatic and extrahepatic HCV-asso ciated auto-
immune diseases, including some malignancies [4]. Figure 1 
shows the variable strength of association between HCV 
and diff erent diseases in the context of HCV syndrome.
Th e pathogenesis of various HCV-associated disorders 
is quite complex and still not completely understood. 
HCV infection is the underlying condition that generally 
precedes by a long time interval the clinical appearance 
of extrahepatic diseases. Th e development of diff erent 
clinical phenotypes is probably the consequence of 
multifactorial and multistep processes together with 
decisive contributions by both genetic and environmental 
co-factors [1-4]. Th is hypothesis is in keeping with the 
strong geographical heterogeneity in the prevalence of 
diff erent HCV-associated diseases [1,3]. HCV lympho-
tro pism [5] is responsible for the B-lymphocyte expansion 
respon sible for the production of large amounts of 
circulating immune complexes, mainly mixed cryo globu-
lins with rheumatoid factor activity, as well as various 
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© 2010 BioMed Central Ltd
Current treatment of hepatitis C-associated 
rheumatic diseases
Clodoveo Ferri1,*, Marco Sebastiani1, Alessandro Antonelli2, Michele Colaci1, A Manfredi1 and Dilia Giuggioli1
R E V I E W
*Correspondence: clferri@unimo.it
1Rheumatology Unit, University of Modena and Reggio Emilia School of Medicine, 
41100 Modena, Italy
Full list of author information is available at the end of the article
Ferri et al. Arthritis Research & Therapy 2012, 14:215 
http://arthritis-research.com/content/14/3/215
© 2012 BioMed Central Ltd
organ- and non-organ-specifi c autoantibodies [1]. 
Interest ingly, the same immunological alterations may 
also be observed in a signifi cant percentage of individuals 
with isolated HCV infection [1,6].
HCV is a positive, single-stranded RNA virus without a 
DNA intermediate in its replicative cycle, so that viral 
genomic sequences cannot be integrated into the host 
genome. Much evidence indicates that HCV infection 
results in chronic stimulation of the immune system, 
which facilitates the clonal B-lymphocyte expansion 
[1,2,7]. Figure  2 (left side) summarizes both virus- and 
host-related co-factors, together with the main biological 
alterations, of the pathogenetic cascade. Th e result may 
be classical MCs or other autoimmune disorders, as well 
as some malignancies, mainly B-cell non-Hodgkin’s lym-
phoma (B-NHL) [1]. Besides MCs, other rheumatic 
diseases can be related to this virus with variable strength 
of association [1,3,8,9]. Th e present review focuses on the 
clinical-serological assessment and therapeutic approach 
to the main HCV-associated rheumatic disorders.
Mixed cryoglobulinemia (cryoglobulinemic 
vasculitis)
Th e pathological hallmark of MCs is the leukocytoclastic 
vasculitis of small arteries, capillaries, and venules; 
there fore, the disease is currently classifi ed among 
systemic vasculitides, in the setting of small-vessel 
vasculitides, and the terms MCs and cryoglobulinemic 
vasculitis should thus be related to the same clinico-
pathological condition [1]. MCs represents the cross-
road between classical rheumatic diseases, such as rheu-
ma toid arthritis (RA) and primary Sjögren’s syndrome 
(pSS), and other autoimmune lymphoproliferative dis-
orders [1] (Figure  1). It is characterized by the typical 
clinical triad of purpura, weakness, and arthralgias and 
by multisystem organ involve ment [1,2]. Th e typical 
cutaneous and visceral organ involvements, such as 
purpura, skin ulcers, and glomerulonephritis, are the 
consequence of the vessel deposition of circulating 
immune complexes, mainly mixed cryoglobulins and 
complement [1]. Liver involve ment, generally a mild to 
moderate chronic hepatitis, may evolve to frank cirrhosis 
in a minority of patients, and is rarely complicated by 
hepatocellular carcinoma [4]. Renal involvement is often 
responsible for membrano proliferative glomerulo neph-
ritis type I; it may severely aff ect the overall prognosis of 
patients with MCs, often in combination with liver 
damage [4]. Peripheral neuro pathy and skin ulcers are 
quite frequent manifes ta tions of MCs; they are barely 
responsive to treatments and consequently may 
Figure 1. Strength of association between hepatitis C virus and diff erent diseases in the context of hepatitis C virus syndrome. The 
spectrum of diff erent hepatitis C virus (HCV)-associated immunological and neoplastic disorders may be classifi ed on the basis of clinico-
epidemiological, histopathological, and molecular biology studies in three diff erent levels. High: the association with HCV infection characterizes 
the large majority of patients; HCV infection is one of the major triggering agents of the disease. Medium: patients with the disease show a 
signifi cantly higher prevalence of HCV infection compared to controls; the putative pathogenetic role of HCV is also supported by pathogenetic 
studies and it may identify at least a specifi c disease subset. Low: the possible association is suggested by limited clinico-epidemiological 
observations; a pathogenetic link in at least a specifi c disease subset from some geographical areas is probable, but needs to be defi nitely 
demonstrated. Other possible associations have been suggested (see text) on the basis of anecdotal observations. B-cell NHL, B-cell non-Hodgkin’s 
lymphoma; HCC, hepatocellular carcinoma.
Ferri et al. Arthritis Research & Therapy 2012, 14:215 
http://arthritis-research.com/content/14/3/215
Page 2 of 11
compromise the patient’s quality of life [4]. Finally, B-
NHL and widespread vasculitis may com pli cate a 
minority of cases; they represent the most harm ful 
manifestations of the disease [1,2,4]. Besides mixed cryo-
globulins in serum, marked reduction of hemolytic 
comple ment activity, with the typical pattern of low, 
often undetectable complement C4, is another hallmark 
of the disease and is particularly useful for disease 
classifi cation [1,10,11]. However, both complement levels 
and cryocrit rarely correlate with the activity/severity of 
MCs; consequently, they are not very useful for clinical 
monitoring of patients and therapeutic decision-making. 
In contrast, the correct evaluation of B-cell expansion, 
which represents the biological substrate of MCs, is 
mandatory because of the possible complication of overt 
lymphoma [1,2,7]. Th is latter event should be suspected 
in the presence of rapid increases of cryocrit and serum 
levels of monoclonal rheumatoid factor and/or comple-
ment C4 [1].
Th e treatment of HCV-associated MCs is particularly 
challenging due to the complex etiopathogenesis and 
clinical polymorphism of the disease. In fact, we can treat 
MCs at three diff erent levels (Figure 2): the chronic HCV 
infection; the immune-pathological alterations, mainly B-
lymphocyte proliferation; and the immune complex-
mediated cryoglobulinemic vasculitis [1,3]. Moreover, 
the correct evaluation of diff erent clinical phenotypes, 
vary ing from mild purpuric lesions, arthralgias, and/or 
Figure 2. The treatment of mixed cryoglobulinemic syndrome must be decided on the basis of the etiopathogenetic cascade that leads 
from hepatitis C virus infection to multiple immune-system alterations, mainly B-cell proliferation, and lastly to immune complex-
mediated small vessel vasculitis. The vasculitic syndrome may be complicated by malignancies, mainly B-cell lymphoma. Accordingly, we can 
treat mixed cryoglobulinemic syndrome (MCs) at three diff erent levels by means of etiological, pathogenetic, and symptomatic therapies. The use 
of antivirals, namely peg-interferon-alpha (peg-IFNα) plus ribavirin (RIBA), aims to eradicate the hepatitis C virus (HCV); it represents the etiological 
treatment of HCV-associated MCs. The anti-CD20 monoclonal antibody rituximab is considered the most useful and safe pathogenetic treatment of 
MCs. In selected patients with severe, active clinical manifestations, sequential or combined therapy with antivirals and rituximab has been usefully 
employed (see also Figure 3). CIC, circulating immune complexes; CPX, cyclophosphamide; HLA, human leukocyte antigen; LAC, low antigen-
content; LDL, low-density lipoprotein; RF, rheumatoid factor.
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weakness to severe organ involvement (renal, liver, 
diff use vasculitis) or malignancies (B-NHL), should 
direct our therapeutic interventions (Figure 3).
HCV infection results in chronic stimulation of the 
immune-system [7], and it may also be responsible for 
either liver damage or neoplastic complications; in theory, 
HCV eradication using alpha-interferon and ribavirin 
should be attempted in all cases [1,3,12,13]. However, a 
benefi cial eff ect of antivirals may be recorded in less than 
half of treated patients and they are often associated with 
important immune-mediated side eff ects, such as 
peripheral sensory-motor neuropathy, thyroiditis, and 
rheumatoid-like polyarthritis [1,3,14]. It is plausible that 
alpha-interferon, which is both an antiviral and immuno-
modulating agent, can foster or exacerbate these 
symptoms, possibly in predisposed subjects.
In the near future, a vaccine-based therapy [15] might 
be able to prevent the progression of HCV infection and 
possibly to interrupt the self-perpetuating autoimmune 
mechanism underlying MCs.
Preliminary studies suggested that some immuno-
modu lat ing therapies in association with antiviral treat-
ment, namely cyclosporine A or TNF inhibitors, have 
synergistic eff ects in the setting of chronic hepatitis type 
C [16,17].
Besides etiological treatments, immunomodulating/
immuno suppressive drugs represent the most useful 
therapies able to aff ect the main pathogenetic mecha-
nisms of MCs, including T- and B-cell proliferation and 
autoantibody production. Th ese treatments include cyclo-
phosphamide and an anti-CD20 monoclonal antibody 
(rituximab) [1,3]. During the past decade, rituximab has 
been increasingly employed for both cutaneous and 
visceral organ involvement of MCs; it can be regarded as 
a useful and safe pathogenetic treatment of cryo globuli-
nemic vasculitis [18]. Its safety was also confi rmed in 
patients with liver damage; interestingly, in patients with 
HCV-associated MCs and advanced cirrhosis, treatment 
with rituximab was able to improve both the cryo globu-
linemic vasculitis and liver function [19]. A compre hen-
sive analysis of the literature regarding the use of 
rituximab and its role in the therapeutic strategy of MCs 
patients has been recently published [18]. Very recently, 
the results of a randomized controlled trial demonstrated 
that anti-CD20 monotherapy also represents a useful and 
safe option for patients with severe MCs [20].
Among symptomatic/pathogenetic treatments, a low 
antigen-content diet can improve the clearance of 
circulating immune complexes by restoring the activity of 
the reticulo-endothelial system, which becomes over-
loaded by large amounts of circulating cryoglobulins [1]. 
Th is reduction in the alimentary input of macromolecules 
with potential antigenic activity may improve the 
function of the mononuclear phagocytic system, which is 
normally impaired in MCs [21]. A low antigen-content 
diet can be usefully employed in patients with clinically 
mild MCs symptoms (arthralgias, weakness, sporadic 
purpura, and/or mild sensory peripheral neuropathy), 
often in asso ciation with low doses of steroids (6-methyl-
prednisolone 2 to 4  mg/day) and/or colchicine. Most 
patients show only mild symptoms for a long time period, 
and are particu larly sensitive to symptomatic treatments 
and to small doses of daily steroid (1 to 2 mg). Clinically 
asymptomatic patients do not usually need any 
treatment, even in the presence of high levels of cryocrit, 
but patients with severe vasculitic manifestations must 
be promptly treated with high doses of steroids and/or 
plasma exchange and/or immunosuppressors; this 
combination therapy is often able to improve the most 
harmful disease complications (Figure 3) [1,4,22].
Th e treatment of cryoglobulinemic skin ulcers is 
particularly challenging. Th ese lesions are prevalent in 
the lower limbs, where other pathogenetic co-factors 
may be associated - namely, venous insuffi  ciency and/or 
arteriosclerotic alterations, which are not rare in older 
patients with comorbidities and/or who have received 
long-term steroid treatment. Th e skin ulcers are painful, 
non-healing, and often complicated by local infection 
and they may severely aff ect patients’ quality of life [4]. 
Figure 4 summarizes the therapeutic strategy for treating 
cryoglobulinemic skin ulcers, including both systemic 
and local treatments at a wound care clinic [23]. Th e 
long-term administration of analgesics is often necessary 
to improve the patient’s chronic pain and their com pli-
ance with local wound care. A team of operators with 
specifi c experience should carry out this integrated 
therapeutic approach [18,23,24].
More recently, some studies have suggested that 
sequential or combined antiviral and immunosuppressive 
therapy could represent a rather useful therapeutic 
strategy for treating MCs [18,25,26]. Th is more aggressive 
treatment could be particularly indicated in patients with 
major clinical manifestations and/or inadequate remis-
sion after standard treatments.
On the whole, careful monitoring of a patient’s clinical 
status is mandatory in clinical practice, with particular 
attention paid to neoplastic complications; in all instances 
the treatment should be tailored to the individual patient 
according to the severity of their MCs symptoms 
(Figure 3) [1].
Given the rarity of the disease and the diffi  culties of 
recruiting clinically homogeneous series of patients, 
there are few controlled randomized trials evaluating the 
usefulness of proposed treatments for MCs. Th e results 
of a consensus conference based on the available 
published studies and expert opinions have been 
summarized in a preliminary core set of therapeutic 
recommendations [27].
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Sicca syndrome/Sjögren’s syndrome
A possible pathogenetic role of HCV in pSS has been 
reported in anecdotal clinical observations [28]. In 
contrast, the frequent association between sicca syn-
drome and HCV infection has been demonstrated by 
both experimental and epidemiological studies focusing 
on the presence of chronic lymphocytic sialadenitis in 
patients with HCV infection [29]. HCV can replicate 
within epithelial cells of the salivary gland of patients 
with sicca syndrome and HCV infection [30].
In clinical practice, the correct diff erential diagnosis 
between some HCV-associated rheumatic disorders and 
classical rheumatic diseases is still under debate, in 
particular between MCs and pSS; this probably refl ects 
the lack of standard classifi cation of these diseases in 
diff erent referral centers.
Figure  5 shows the main clinico-pathological and 
immuno logical diff erences between MCs and other 
possible HCV-associated diseases. Patients with MCs 
may develop a mild sicca syndrome in the absence of 
typical histopathological and/or serological alterations 
[1]. On the other hand, the detection of mixed 
cryoglobulins in the serum of a minority of pSS cases 
seems to identify a particular clinical subset characterized 
by worse prognosis and frequent evolution to malignant 
B-NHL [31]. In individual cases the diff erential diagnosis 
between pSS and MCs may be very diffi  cult, mainly in 
patients with overt sicca syndrome, cryoglobulinemia, 
and HCV infection [1]. Th erefore, it is correct to classify 
these patients as overlapping MCs/pSS [1], and the 
therapeutic approach should consequently be decided 
after careful evaluation of the main clinical manifes ta-
tion(s), including the presence/severity of type C 
hepatitis.
Antiviral treatment with IFNα and ribavirin seems to 
improve sicca syndrome in HCV-positive patients, even 
if serious immune-mediated adverse events have been 
observed [32]. Besides topical treatments that may 
Figure 3. The therapeutic strategy for mixed cryoglobulinemic syndrome may be modulated according to the clinical status of individual 
patients. We can consider at least four clinical conditions. Mixed cryoglobulinemic syndrome (MCs) may be completely asymptomatic or it may 
sporadically show very mild manifestations, such as fl eeting purpuric lesions on the legs; in these cases monitoring may be suffi  cient, while an 
attempt at HCV eradication may be considered. On the opposite side are patients with severe, rapidly progressive cryoglobulinemic vasculitis 
that must be treated with aggressive combined treatment similar to that used for other systemic vasculitides. Sequential or combined treatment 
with antivirals and rituximab may be usefully employed in selected patients with severe manifestations. The order of sequential treatment may 
be decided on the basis of prevalent organ manifestation(s), even if the combined therapy seems to be comparable for effi  cacy and safety. CPX, 
cyclophosphamide; CS, corticosteroid; LAC, low antigen-content; peg-IFN, peg-interferon;  RIBA, ribavirin; RTX, rituximab.
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partially improve patients’ quality of life, there is no 
specifi c systemic treatment for HCV-associated sicca 
syndrome. As for classical MCs or pSS, the possible 
complication with malignant lymphomas must also be 
taken into account in these patients [28,31].
Arthritis
While arthralgias are one of the most common extra-
hepatic manifestations of HCV infection, chronic arthritis 
is signifi cantly less common [4,8,9]. When present, it is 
often a less aggressive oligo-polyarthritis compared to 
classical RA. Patients with HCV-associated MCs present 
with arthralgias, while infl ammatory joint involvement is 
quite rare and generally characterized by mild oligo-
arthritis [4]. A symmetrical rheumatoid-like polyarthritis 
may complicate IFN treatment in HCV-positive patients 
[9]. Because of the relatively high prevalence of the two 
diseases, it is not rare to observe a simple association 
between classical RA and HCV infection. Figure  5 
summar izes the main clinico-serological parameters for 
diff erential diagnosis between classical RA and other 
HCV-associated disorders [1,3,4,8,28,31,33,34]. In patients 
presenting with chronic arthritis, the presence of hepato-
tropic virus infection (that is, HCV and hepatitis B virus) 
must be ruled out because of the possible severe, often 
life-threatening side eff ects of disease-modifying anti-
rheumatic drugs (DMARDs) and biologics [35]. Several 
diff erent viral infections may trigger symmetrical arthritis 
mimicking classical RA and clinical work-up including 
virological investigations should therefore be done at the 
patient’s fi rst assessment (Figure 6).
Patients who present with both HCV infection and 
arthritis can either have a simple comorbidity of RA and 
HCV infection or HCV-associated arthritis, with or 
without MCs. Th e fi rst may be treated with standard 
strategies used for RA with some precautions in 
consideration of the concomitant viral infection and 
possible liver involvement. Some DMARDs, in particular 
methotrexate and lefl unomide, may be employed after 
carefully evaluat ing and monitoring liver involvement, 
while biologics such as anti-TNFα and rituximab have 
been usefully employed without signifi cant side eff ects in 
HCV-positive RA patients [36]. Interestingly, these 
biologic therapies, as well as cyclosporine A, seem to 
have a potential synergistic eff ect with antiviral treat-
ments for hepatitis C [16,17]. Th erefore, careful hepato-
logic evaluation of these patients is always mandatory, 
taking into account the opportunity for antiviral treat-
ment [35].
On the whole, patients with concomitant RA and HCV 
infection require the same clinical assessment and 
monitor ing as patients with HCV-associated arthritis 
with or without MCs; they may have an increased risk to 
develop some HCV-associated complications, such as 
B-cell NHL, even as a consequence of immunomodulating 
therapies.
Figure 4. Therapeutic strategy for treating cryoglobulinemic cutaneous ulcers should be based on both systemic and local treatments. 
After clinical work-up considering the entire MCs, including possible comorbidities (venous insuffi  ciency and/or arteriosclerotic alterations, 
diabetes, and so on), and careful examination of the ulcer characteristics, the systemic treatment may be based on etiological, pathogenetic, and/
or symptomatic therapies. More aggressive combined treatments (immunosuppressors, steroids, and plasmapheresis) may be necessary in the 
presence of very severe, non-healing skin ulcers. Long-term administration of analgesics is often necessary to improve the patient’s chronic pain 
and compliance with local treatment, which should be carried out at a wound care clinic. Wound bed preparation, with particular regard to the 
prevention and treatment of infections, is crucial for the healing of cryoglobulinemic skin ulcers. CPX, cyclophosphamide; peg-IFN, peg-interferon;  
RIBA, ribavirin; RTX, rituximab.
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Usually, HCV-associated arthritis is poorly aggressive 
and the patients may respond to low doses of steroids 
and hydroxychloroquine. Th e use of other DMARDs 
presents the above-mentioned limitations. On the 
contrary, rituximab may be usefully employed, mainly in 
patients with more aggressive disease, and may represent 
the fi rst-choice treatment in patients with arthritis in the 
setting of MCs [18].
Other possible HCV-related rheumatic diseases
Besides the HCV-related conditions described above, 
other rheumatic diseases have been suggested to be 
associated with HCV infection; namely, osteosclerosis, 
myalgia, fi bromyalgia, poly/dermatomyositis, polyarteritis 
nodosa, Beçhet’s syndrome, systemic lupus erythema to-
sus, and antiphospholipid syndrome [1,8,9,29].
Osteosclerosis is a very uncommon condition des-
cribed in adults infected with HCV and can be defi ned as 
an acquired, painful skeletal disorder characterized by a 
marked increase of bone mass [37-40]. Clinically, osteo-
sclerosis is characterized by nonspecifi c, often diff use 
bony pain and tenderness over involved bones due to 
periosteal stretching, in the absence of joint swelling or 
motion limitation. Radiographic examination shows bony 
sclerosis and thickening of the long-bone cortices, mainly 
diaphyseal cortical bone. Laboratory investigations 
frequently reveal abnormally increased markers of bone 
formation (alkaline phosphatase, bone-specifi c alkaline 
Figure 5. Diff erential diagnosis between some important hepatitis C virus-associated rheumatic manifestations and classical diseases 
such as primary Sjögren’s syndrome and rheumatoid arthritis is possible on the basis of clinico-serological and pathological features. 
Some important fi ndings may be usefully employed for a correct diagnosis: the histopathological characteristics and severity of salivary 
gland involvement and specifi c autoantibodies (anti-SSA/SSB) are rarely found in hepatitis C virus (HCV)-associated sicca syndrome or mixed 
cryoglobulinemia syndrome (MCs) patients. Conversely, cutaneous leukocytoclastic vasculitis, visceral organ involvement (hepatitis, membrano-
proliferative-glomerulonephritis), abnormally low complement C4, and HCV infection, typically found in MCs, are very uncommon in primary 
Sjögren’s syndrome (pSS). Both MCs and pSS may be complicated by B-cell non-Hodgkin’s lymphoma (B-cell NHL), and less frequently also 
rheumatoid arthritis patients. Finally, erosive symmetrical polyarthritis and serum anti-cyclic citrullinated peptide (anti-CCP) antibodies are specifi c 
diagnostic fi ndings of classical rheumatoid arthritis, but generally absent in HCV-associated arthritis. However, there is a gray area of clinical overlap 
between diff erent disorders. RF, rheumatoid factor.
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phosphatase, and osteocalcin); these alterations were 
mirrored by the marked increase of bone mass (bone 
mineral density) and enhanced radionuclide uptake at 
scintigraphy (99mTc-MDP). Bone biopsy shows increased 
numbers and thick ness of trabeculae with parallel 
reduction of bone marrow [37-40]. Th e pathogenesis of 
this rare syndrome is still unknown. It has been suggested 
that HCV alone or in combination with other unknown 
agent(s) may infect and alter bone cells or their pre-
cursors in predisposed subjects. Th ese alterations might 
be mediated by the produc tion of bone growth factors, 
such as insulin-like growth factors or osteoprotegerin. 
Th e pathogenetic role of this latter factor seems to be 
relevant as an imbalance in the osteoprotegerin/RANKL 
(receptor activator of nuclear factor kappa-B ligand) 
system leading to a pre dominance of osteoprotegerin has 
been documented [38]. With regards to therapeutic 
approaches to osteo sclerosis, attempts to treat with anti-
resorptive agents in at least seven patients was ineff ective, 
while symptomatic treatments may provide some benefi t. 
In some cases a partial or complete spontaneous 
remission of symptoms and/or bone sclerosis was 
Figure 6. Diff erential diagnosis among patients with arthritis and concomitant hepatitis C virus infection, and therapeutic strategies. 
Clinico-serological and virological work-up is mandatory in patients presenting with chronic arthritis. Patients with polyarthritis and hepatitis C 
virus (HCV) infection can be classifi ed as either having simple comorbidity, that is, HCV infection and rheumatoid arthritis (RA) or other forms 
of chronic arthritis, or having HCV-associated arthritis. This latter may represent one extrahepatic manifestation of HCV infection or it can be a 
symptom of MCs. The comorbidity may be treated with the standard therapeutic strategies for RA, with some precautions because of concomitant 
viral infection, in particular for methotrexate and lefl unomide. On the contrary, biologics (anti-TNFα and anti-CD20 rituximab) have been usefully 
employed without signifi cant side eff ects in HCV-positive RA patients. The antiviral therapy of IFNα plus ribavirin (RIBA) can also be employed 
after careful hepatologic evaluation of patients. Interestingly, anti-TNFα, rituximab, and cyclosporine A seem to have a potential synergistic eff ect 
if associated with antiviral treatment (IFNα + RIBA). Usually, HCV-associated arthritis is poorly aggressive and may respond to low doses of steroids 
and hydroxychloroquine (HCQ). The use of other disease-modifying anti-rheumatic drugs (DMARDs) presents the above-mentioned limitations, 
while rituximab may be usefully employed, especially in patients with more aggressive arthritis. Finally, rituximab may represent the fi rst-choice 
treatment in patients with arthritis in the setting of MCs. Ab, antibody; CCP, cyclic citrullinated peptide; RF, rheumatoid factor.
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observed during follow-up [37-40]. Anecdotally, in a 
recently published case report the antiviral therapy was 
followed by a recovery of skeletal sclerosis [40].
Myalgia has been recorded in a signifi cant number 
(15%) of patients from a large series of HCV-infected 
individuals [29]. Th e pathogenesis of this symptom 
remains diffi  cult to explain, although the detection of 
viral genomic sequences within muscle fi bers suggested a 
direct involvement of HCV in the pathogenesis of diff use 
muscle pain [41]. Fibromyalgia has also been reported by 
some studies in a signifi cant percentage of patients with 
chronic HCV infection [42], but other studies in series of 
patients with typical fi bromyalgia have not confi rmed 
this association [9,43]. On the other hand, the diff erential 
diagnosis between fi bromyalgia and muscle pain, 
frequently associated with weakness and arthralgias, may 
be very diffi  cult in the setting of HCV-positive patients. 
With regard to sicca syndrome and pSS, some authors 
prefer to maintain HCV-associated myalgia and classical 
fi bromyalgia as distinct entities [9,43].
Several case reports in the literature have documented 
an association between poly-dermatomyositis and HCV 
infection [1,8,9,29,44]. Generally, these disorders appear 
in patients with long-lasting viral infection or may 
complicate IFNα treatment [45]. Similarly, cases of 
vasculitis involving medium-sized arteries suggesting the 
diagnosis of polyarteritis nodosa have been associated 
with HCV infection [29,46]. In addition, HCV sero-
positivity has been reported in a signifi cant percentage of 
patients with polyarteritis nodosa [46]. Th is possible 
association is not surprising considering the well-known 
relationship between polyarteritis nodosa and another 
hepatotropic virus, hepatitis B virus, which is responsible 
for a signifi cant number of patients with this vasculitis 
[47]. Poly arteritis nodosa may share numerous clinical 
symptoms with MCs; thus, patients with suspected HCV-
associated polyarteritis nodosa should be correctly 
classifi ed by means of wide clinico-serological and patho-
logical work-up.
With regard to other possible HCV-associated dis-
orders, namely Beçhet’s syndrome, systemic lupus erythe-
ma tosus, and antiphospholipid syndrome, data reported 
in the literature are generally anecdotal [8,9,29,48,49]. 
Even if a possible causative role of HCV in these auto-
immune diseases cannot be totally excluded, these 
patients might be better classifi ed as having a simple 
comorbidity. However, they invariably represent a 
troublesome clinical condition, mainly with regards to 
therapeutic approach.
As for HCV-associated MCs, patients with conco-
mitant autoimmune systemic disorders, such as poly/
dermatomyositis, polyarteritis nodosa, systemic lupus 
erythematosus, and HCV infection may be usefully treated 
with immunesuppressors (for example, cyclo phos phamide 
and rituximab) with some important pre cautions and 
limitations due to viral infection. In all instances, a 
preliminary clinical evaluation of liver condition and viral 
replication is necessary before any therapeutic decisions 
are made. Th ese latter may be based on standard 
immunosuppressive treatments, possibly integrated by 
sequential/combined antiviral treatment.
Conclusion
HCV-associated disorders include a spectrum of diff erent 
immunological and neoplastic manifestations, among 
which are some rheumatic diseases. On the basis of 
clinico-epidemiological, histopathological, and molecular 
biology studies, the strength of association between HCV 
and a given disease varies largely among diff erent 
diseases and, more interestingly, for each disease among 
patient series from diff erent countries.
Autoimmune systemic diseases often represent a 
clinical syndrome, which may include diff erent clinico-
serological subsets. Th ese latter are the resulting pheno-
types of multiple genetic, environmental, and infectious 
pathogenetic cofactors. MCs represents an important 
example of these multifactorial and clinically multifaceted 
disorders, potentially triggered by HCV infection in a 
variable percentage of cases. Considering the wide range 
of clinical phenotypes, some HCV-associated diseases 
may present important classifi catory/diagnostic diffi  cul-
ties, and may constitute a real therapeutic dilemma 
because of the coexistence of autoimmune manifestations 
and viral infection.
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